SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)

• Rosario García-Campelo ^[1] ; Ivana Sullivan ^[2] ; Edurne Arriola ^[7] ; Amelia Insa ^[8] ; Oscar Juan Vidal ^[9] ; Patricia Cruz-Castellanos ^[3] ; Teresa Morán ^[4] ; Noemí Reguart ^[10] ; Jon Zugazagoitia ^[5] ; Manuel Dómine ^[6]
  1. [1] Complexo Hospitalario Universitario da Coruña

     Complexo Hospitalario Universitario da Coruña

     A Coruña, España

     
  2. [2] Hospital de la Santa Creu i Sant Pau

     Hospital de la Santa Creu i Sant Pau

     Barcelona, España

     
  3. [3] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  4. [4] Universitat Autònoma de Barcelona

     Universitat Autònoma de Barcelona

     Barcelona, España

     
  5. [5] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  6. [6] Fundación Jiménez Díaz

     Fundación Jiménez Díaz

     Madrid, España

     
  7. [7] Servicio de Oncología Médica, Hospital del Mar-CIBERONC, Barcelona, España
  8. [8] Servicio de Oncología Médica, Hospital Clínico de Valencia, Valencia, España
  9. [9] Servicio de Oncología Médica, Hospital Universitari i Politécnic La Fe de Valencia, Valencia, España
  10. [10] Servicio de Oncología Médica, Hospital Clinic, Barcelona, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 25, Nº. 9 (September), 2023, págs. 2679-2691
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Small-cell lung cancer (SCLC) is a highly aggressive malignancy comprising approximately 15% of lung cancers. Only one-third of patients are diagnosed at limited-stage (LS). Surgical resection can be curative in early stages, followed by platinum–etoposide adjuvant therapy, although only a minority of patients with SCLC qualify for surgery. Concurrent chemo-radiotherapy is the standard of care for LS-SCLC that is not surgically resectable, followed by prophylactic cranial irradiation (PCI) for patients without progression. For extensive-stage (ES)-SCLC, a combination of platinum and etoposide has historically been a mainstay of treatment. Recently, the efficacy of programmed death-ligand 1 inhibitors combined with chemotherapy has become the new front-line standard of care for ES-SCLC. Emerging knowledge regarding SCLC biology, including genomic characterization and molecular subtyping, and new treatment approaches will potentially lead to advances in SCLC patient care.